finance.yahoo.comNew BRIUMVI (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis9 months ago
finance.yahoo.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting10 months ago
finance.yahoo.comFDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment10 months ago
businesswire.comPrecision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis11 months ago
businesswire.comPrecision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis11 months ago